Acquired and Genetic Amyloid Neuropathies.

Amyloidosis is a potentially treatable cause of polyneuropathy with various distinct etiologies, including amyloid light chain (AL), transthyretin variant (ATTRv), wild-type transthyretin amyloidosis (wrATTR), gelsolin, and apolipoprotein A1 (ApoA-I). Among these, AL and transthyretin amyloidosis are the most common, while AGel and ApoA-I amyloidosis present more complex diagnostic challenges due to their rarity. Despite advances in the recognition and treatment of AL and transthyretin amyloid protein amyloidosis, diagnostic delays remain a concern. Accurate diagnosis hinges on genetic testing, biomarker development, and tissue biopsy with Congo red staining. Multidisciplinary collaboration, including neurologists, is crucial for optimizing patient outcomes across all forms of amyloidosis.